Glaucoma: genes, phenotypes, and new directions for therapy

Bao Jian Fan, Janey L. Wiggs

*J Clin Invest.* 2010;120(9):3064-3072. https://doi.org/10.1172/JCI43085.

**Review**

Glaucoma, a leading cause of blindness worldwide, is characterized by progressive optic nerve damage, usually associated with intraocular pressure. Although the clinical progression of the disease is well defined, the molecular events responsible for glaucoma are currently poorly understood and current therapeutic strategies are not curative. This review summarizes the human genetics and genomic approaches that have shed light on the complex inheritance of glaucoma genes and the potential for gene-based and cellular therapies that this research makes possible.

Find the latest version:

http://jci.me/43085-pdf
Glaucoma, a leading cause of blindness worldwide, is characterized by progressive optic nerve damage, usually associated with intraocular pressure. Although the clinical progression of the disease is well defined, the molecular events responsible for glaucoma are currently poorly understood and current therapeutic strategies are not curative. This review summarizes the human genetics and genomic approaches that have shed light on the complex inheritance of glaucoma genes and the potential for gene-based and cellular therapies that this research makes possible.

Introduction
Glaucoma is a term used to describe a group of disorders that have in common a distinct type of optic nerve damage, causing irreversible defects in the visual field. The optic neuropathy is progressive and, if left untreated, results in absolute blindness. Glaucoma is a leading cause of blindness worldwide, affecting 2% of individuals of European descent and up to 10% of individuals of sub-Saharan African descent over 50 years of age (1). The disease process is insidious, and since central vision is usually not lost until the disease is advanced, a significant proportion of individuals remain either undiagnosed or undertreated. The most common forms of glaucoma are age-related, beginning in midlife and progressing slowly but relentlessly (2). If detected early enough, disease progression can be slowed with drug and/or surgical treatment, underscoring the importance of identifying the disease in its earliest stages (2).

Elevated intraocular pressure (IOP) is a major risk factor for glaucoma. Fluid formed by the ciliary body (aqueous humor) is removed by the trabecular outflow pathways, which includes the trabecular meshwork (made up by the uveal and corneoscleral meshworks), the juxtacanalicular connective tissue, the endothelial lining of Schlemm’s canal, and the collecting channels and the aqueous veins (2). The trabecular meshwork outflow pathways provide resistance to aqueous fluid outflow (3) and normally functions to maintain a minimum level of eye pressure that keeps the eye in the round shape necessary for its refractive properties. The IOP is dependent on the rate of fluid removal, which under normal conditions matches the rate of formation. In most patients with glaucoma, the rate of fluid removal declines so that it no longer keeps pace with the rate of formation, and the IOP increases. Some fluid can exit the eye through an alternative pathway (uveoscleral pathway); however, this is not sufficient to maintain homeostasis (Figure 1).

The molecular events responsible for a decrease in aqueous outflow in most patients with glaucoma are not known. Current treatment for glaucoma is directed toward lowering the IOP by reducing the amount of fluid made by the ciliary body, increasing the flow of fluid through the trabecular meshwork or uveoscleral pathways, and/or by surgically creating an alternative path for fluid egress. None of these approaches are curative, and over time multiple treatments are generally required to limit disease progression (4). Loss of visual function in glaucoma is caused by apoptosis of retinal ganglion cells, leading to a loss of ganglion cell axons and degeneration of the optic nerve. Retinal ganglion cell loss results in permanent visual field defects that progressively enlarge and can eventually cause total blindness. Ganglion cell loss is usually, but not always, associated with elevated IOP (5). Progressive ganglion cell loss without increased IOP is called normal tension glaucoma (NTG) (6).

The molecular events responsible for glaucoma are currently poorly understood, complicating the design of therapies based on the underlying disease mechanisms. Most forms of glaucoma are inherited, either as common complex traits or as mendelian autosomal dominant or recessive traits (early onset). This review summarizes the glaucoma genes and phenotypes identified using genetic and genomic approaches and the potential for gene-based and cellular therapies granted by this emerging science.

Genes identified using linkage approaches and multiplex families
Large multiplex families suitable for linkage analysis are typically affected by early-onset forms of glaucoma inherited as mendelian dominant or recessive traits. Most pedigrees affected by adult-onset forms of glaucoma do not have the sufficient size and structure required for linkage studies, because the older age of onset typically limits these pedigrees to one and possibly two affected generations (7). To date, at least 29 genetic loci for various forms of glaucoma have been defined by linkage studies (8, 9), and 12 causative genes have been identified from these loci (Table 1). Genes and loci for different phenotypic forms of glaucoma are summarized below.

Congenital glaucoma. The onset of congenital glaucoma is typically before 3 years of age and is characterized by very high IOP caused by abnormal development of the trabecular outflow pathways (10). This form of glaucoma is typically inherited as an autosomal recessive trait and is more common in countries and cultures that practice consanguinity. Linkage studies have identified four loci, GLC3A (2p22-p21) (11), GLC3B (1p36.2-p36.1) (12), GLC3C (14q24.3) (13), and GLC3D (14q24) (14), and two genes, CYP1B1, coding for cytochrome P450, family 1, subfamily B, polypeptide 1 at GLC3A (15), and more recently, LTBP2, coding for latent transforming growth factor-β-binding protein 2 at GLC3D (16, 17). Although known to cause congenital glaucoma for over a decade, the role of cytochrome P450 1B1 in glaucoma pathogenesis and development of the trabecular meshwork is not yet known but is hypothesized to participate in the metabolism of...
endogenous molecules that are necessary for ocular development (18, 19). Latent transforming growth factor-β-binding protein 2 is an ECM protein with homology to fibrillins and may participate in cell adhesion and may have a structural role in the development of the ocular outflow pathways (18, 19).

**Anterior segment dysgenesis syndromes.** The anterior segment of the eye includes all the structures in front of the ocular lens (iris, trabecular meshwork, anterior chamber, aqueous humor, and cornea). A majority of these structures arise from the cranial neural crest, and mutations in genes controlling ocular developmental processes result in abnormal formation of the trabecular meshwork and other structures necessary for fluid removal, causing an early onset (typically between 10 to 20 years of age) of very high IOP (20). These developmental disorders are usually inherited as autosomal dominant traits and may be associated with systemic abnormalities (20). For example, in addition to ocular dysgenesis, patients affected by Axenfeld-RieGER syndrome have abnormal teeth and hearing loss (21). Several loci and two genes coding for transcription factors (paired-like homeodomain transcription factor 2 [PITX2] at RIEG1, ref. 22, and forkhead box C1 [FOXC1] at RIEG3, ref. 23) have been associated with this syndrome. Other genes causing developmental glaucoma are PAX6 (Aniridia) (24) and LMX1B (nail-patella syndrome and anterior segment dysgenesis) (25, 26). Interestingly, the developmental glaucoma syndromes frequently exhibit variable expressivity, with glaucoma only occurring in about 50% of cases overall (27). The cause of the variable expressivity is not known; however, it may be secondary to modifier genes or stochastic effects (28).

**Nanophthalmos.** Nanophthalmos is a developmental disorder that causes the eye to be smaller than normal (29). The reduced size of the eye crowds the intraocular structures, which increases the risk of a form of glaucoma called angle-closure glaucoma (29). Three loci (NNO1–NNO3) and one gene (membrane frizzled-related protein [MFRP] at NNO2) have been identified for this condition (30–32). The function of the MFRP protein is not completely understood; however, it appears to be necessary for retinal development, particularly the photoreceptor layer of the retina (33). When the retinal photoreceptors do not form normally, the eye is smaller, shorter, and predisposed to angle-closure glaucoma (33).

**Pigment dispersion syndrome and pigmentary glaucoma.** Pigment dispersion syndrome is an ocular condition characterized by shedding of pigment granules from the iris, which become distributed throughout the eye, including the trabecular outflow pathways (34). The presence of pigment in the outflow pathways causes an increase in IOP and glaucoma in approximately 50% of individuals affected with the condition (34). The condition can be inherited as an autosomal dominant trait, and one loci (GPDS1) has been identified; however, the causative gene has not yet been discovered (35). The DBA/2J mouse spontaneously develops glaucoma that is clinically similar to human pigmentary glaucoma; however, the genes responsible for the mouse phenotype do not cause the disease in humans (36, 37).

**Juvenile open-angle glaucoma.** The term open-angle glaucoma refers to forms of glaucoma occurring in eyes with normal anatomic structures. Usually, open-angle glaucoma develops in adults after 50 years of age (called primary open-angle glaucoma [POAG]), but rarely this type of glaucoma can develop in a child or young adult before 35 years of age. This early-onset form of POAG, called JOAG, is inherited as an autosomal dominant trait (38) and is characterized by extremely high IOP, usually requiring surgical treatment (39, 40). A number of genetic loci have been identified for this condition, GLC1A (1q24.3-q25.2) (41), GLC1F (9q22) (42), GLC1K (20p12) (42), GLC1M (5q22.1-q32) (43–45), and GLC1N (15q22-q24) (46), and one gene, MYOC, coding for Myocilin, has been identified from the GLC1A locus (47, 48). Myocilin is an extracellular protein of unknown ocular function. Missense changes in the protein account for 10% of the cases of JOAG and also 3%–5% of the cases of adult-onset POAG (49, 50). A loss of protein function does not result in glaucoma (51, 52), and the underlying genetic mechanism is likely to be a gain-of-function or dominant-negative effect (53). The disease-associated missense changes reduce the solubility of the protein, causing it to aggregate in the endoplasmic reticulum and preventing its secretion to the ECM (54). Since an absence of protein does not

**Figure 1**

Schematic diagram of eye structures involved in aqueous humor dynamics. Aqueous humor is produced by the ciliary body and passes from the posterior chamber through the pupil into the anterior chamber into the trabecular meshwork, Schlemm’s canal, and finally into the episcleral venous system. The alternative path is the “uveoscleral outflow” that drains fluid through the ciliary muscle into the supraciliary and suprachoroidal spaces and then out of the eye through the sclera. Approximately 80% of aqueous humor is removed by the conventional trabecular meshwork pathway, and the remainder is removed by the uveoscleral pathway. Elevated IOP in glaucoma is caused by alterations to the conventional trabecular meshwork pathway. The figure adapted from Berwick Eye and Surgicentre (www.berwickeye.com.au/glaucoma.htm).
cause disease, it remains unknown why the aggregation of myocilin intracellularly results in elevated IOP; however, recent work suggests that accumulation of myocilin aggregates intracellularly may sensitize trabecular meshwork cells to apoptosis (55).

**Adult-onset POAG.** Many patients with adult-onset POAG have affected family members, making model-independent (genetic linkage studies that do not assume a specific inheritance model and are usually sibpair based) and model-dependent linkage approaches (linkage studies that require an inheritance model, i.e., autosomal dominant or autosomal recessive, to be defined) to gene identification possible. Model-dependent linkage analyses using multiplex POAG pedigrees have yielded a number of potential POAG loci (GLC1A–GLC1H and GLC1J; Table 1) but few genes. Optineurin (OPTN) at GLC1E (10p15-p14) (56), although initially described as a POAG-causative gene, is primarily responsible for rare cases of familial NTG, a type of open-angle glaucoma in which the optic nerve deteriorates despite normal IOP (57, 58). Optineurin may influence ganglion cell apoptosis directly through rab8 signaling (59, 60). WD repeat domain 36 (WDR36) at GLC1G (5q21.3-q22.1) appears to contribute to POAG severity in some cases but is not necessary or sufficient for disease development (61, 62). A zebrafish homolog of WDR36 stimulates apoptosis mediated by p53, suggesting a role for WDR36 in retinal ganglion cell susceptibility to apoptotic cell death (63). Genome-wide scans using nonparametric (model-free) linkage methods have also been completed for POAG pedigrees of European descent (64), Caribbean pedigrees of African descent in Barbados (65), and African-American pedigrees with diabetes and elevated IOP (66). These scans, using between 373 and 445 microsatellite repeat markers, identified 10 genomic regions that may harbor POAG susceptibility genes (2p14, 2q33-34, 10-12-p13, 14q11-q22, 17p13, 17q25, 19q12-q14). A follow-up study of the scan performed on pedigrees of European descent, using ordered subset analysis with the mean family age of onset as a covariate, identified a subset of 15 families with significant linkage to 15q11-q13, designated GLC1I (67). Recent studies suggest that the neurotrophin 4 (NTF4) gene located in the 19p13.3 region (GLC1O) may contribute to POAG in a German population (68). Alterations in neurotrophin 4 are predicted to have decreased affinity

### Table 1

<table>
<thead>
<tr>
<th>Chromosome location</th>
<th>Locus</th>
<th>Gene</th>
<th>Condition</th>
<th>Inheritance pattern</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1q24.3-q25.2</td>
<td>GLC1A</td>
<td>MYOC</td>
<td>JOAG and adult-onset POAG</td>
<td>JOAG, AD</td>
<td>41, 47, 48</td>
</tr>
<tr>
<td>1p36.2-p36.1</td>
<td>GLC3B</td>
<td></td>
<td>Congenital glaucoma</td>
<td>AR</td>
<td>12</td>
</tr>
<tr>
<td>2p15-p16</td>
<td>GLC1H</td>
<td></td>
<td>Adult-onset POAG</td>
<td>AD</td>
<td>124</td>
</tr>
<tr>
<td>2p22-p21</td>
<td>GLC3A</td>
<td>CYP1B1</td>
<td>Congenital glaucoma</td>
<td>AR</td>
<td>11, 15</td>
</tr>
<tr>
<td>2cen-q13</td>
<td>GLC1B</td>
<td></td>
<td>Adult-onset POAG</td>
<td>AD</td>
<td>125</td>
</tr>
<tr>
<td>2q11-q14</td>
<td>NNO3</td>
<td>Nanophthalmos</td>
<td>AD</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>3p22-p21</td>
<td>GLC1L</td>
<td></td>
<td>Adult-onset POAG; NTG</td>
<td>AD</td>
<td>126</td>
</tr>
<tr>
<td>3q21-q24</td>
<td>GLC1C</td>
<td></td>
<td>Adult-onset POAG</td>
<td>AD</td>
<td>127</td>
</tr>
<tr>
<td>4q25-q26</td>
<td>RIEG1; IRID2</td>
<td>PITX2</td>
<td>Axenfeld-Rieger syndrome; Iridogoniodygenesis</td>
<td>AD</td>
<td>22</td>
</tr>
<tr>
<td>5q21.3-q22.1</td>
<td>GLC1G</td>
<td>WDR36</td>
<td>Adult-onset POAG</td>
<td>AD; complex</td>
<td>61, 62</td>
</tr>
<tr>
<td>5q22.1-q32</td>
<td>GLC1M</td>
<td></td>
<td>JOAG</td>
<td>AD</td>
<td>43–45</td>
</tr>
<tr>
<td>6p25</td>
<td>RIEG3; IRID1</td>
<td>FOXC1</td>
<td>Axenfeld-Rieger syndrome; Iridogoniodygenesis</td>
<td>AD</td>
<td>23</td>
</tr>
<tr>
<td>7q35-q36</td>
<td>GLC1F</td>
<td></td>
<td>Adult-onset POAG</td>
<td>AD</td>
<td>128</td>
</tr>
<tr>
<td>7q35-q36</td>
<td>GPDS1</td>
<td></td>
<td>Pigment dispersion syndrome</td>
<td>AD</td>
<td>35</td>
</tr>
<tr>
<td>8q23</td>
<td>GLC1D</td>
<td></td>
<td>Adult-onset POAG</td>
<td>AD</td>
<td>129</td>
</tr>
<tr>
<td>9q22</td>
<td>GLC1J</td>
<td></td>
<td>JOAG</td>
<td>AD</td>
<td>42</td>
</tr>
<tr>
<td>9q34.1</td>
<td>NPS</td>
<td>LMX1B</td>
<td>Nail-patella syndrome</td>
<td>AD</td>
<td>25, 26</td>
</tr>
<tr>
<td>10p15-p14</td>
<td>GLC1E</td>
<td>OPTN</td>
<td>Adult-onset POAG; NTG</td>
<td>AD</td>
<td>56, 59, 60</td>
</tr>
<tr>
<td>11p</td>
<td>NNO1</td>
<td></td>
<td>Nanophthalmos</td>
<td>AD</td>
<td>30</td>
</tr>
<tr>
<td>11p13</td>
<td>AN</td>
<td>PAX6</td>
<td>Aniridia</td>
<td>AD</td>
<td>24</td>
</tr>
<tr>
<td>11q23</td>
<td>NNO2</td>
<td>MFRP</td>
<td>Nanophthalmos</td>
<td>AR</td>
<td>31, 33</td>
</tr>
<tr>
<td>13q14</td>
<td>RIEG2</td>
<td></td>
<td>Axenfeld-Rieger syndrome</td>
<td>AD</td>
<td>130</td>
</tr>
<tr>
<td>14q24.3</td>
<td>GLC3C</td>
<td></td>
<td>Congenital glaucoma</td>
<td>AR</td>
<td>13, 16, 17</td>
</tr>
<tr>
<td>14q24</td>
<td>GLC3D</td>
<td>LTBP2</td>
<td>Congenital glaucoma</td>
<td>AR</td>
<td>14</td>
</tr>
<tr>
<td>15q11-q13</td>
<td>GLC1I</td>
<td></td>
<td>Adult-onset POAG</td>
<td>Complex</td>
<td>67</td>
</tr>
<tr>
<td>15q22</td>
<td>XFS</td>
<td>LOXL1</td>
<td>Exfoliation glaucoma</td>
<td>Complex</td>
<td>71–76</td>
</tr>
<tr>
<td>15q22-q24</td>
<td>GLC1N</td>
<td></td>
<td>JOAG</td>
<td>AD</td>
<td>46</td>
</tr>
<tr>
<td>19q13.3</td>
<td>GLC1O</td>
<td>NTF4</td>
<td>Adult-onset POAG; NTG</td>
<td>Complex</td>
<td>68</td>
</tr>
<tr>
<td>20p12</td>
<td>GLC1K</td>
<td></td>
<td>JOAG</td>
<td>AD</td>
<td>42</td>
</tr>
</tbody>
</table>

AD, autosomal dominant; AR, autosomal recessive.
with its specific receptor, tyrosine kinase receptor B (TrkB), leading to decreased activation of TrkB. These findings suggest that loss of neurotrophic function may be one of the general mechanisms involved in the pathogenesis of glaucoma and that agents activating TrkB could be considered as neuroprotective targets.

**Case-control association studies: POAG and NTG**

It is likely that multiple genes and/or environmental factors contribute to the complex inheritance of adult-onset glaucoma and that different sets of genetic and environmental risk factors contribute to the regulation of IOP and ganglion cell apoptosis. A number of candidate genes have been evaluated for association with POAG and NTG; however, the strength of association is variable among these studies, and most have not been replicated in other studies or populations (Table 2). A gene-environment interaction has been observed between nitric oxide synthetase 3 (NOS3) SNPs and female sex and postmenopausal hormone use in the women in relation to POAG (69). Other gene-environment and gene-gene interactions are likely to contribute to POAG.

**Genome-wide association studies**

**Exfoliation syndrome and glaucoma.** Of the adult-onset forms of glaucoma, a sufficiently powered genome-wide association study has only been completed for exfoliation glaucoma. Exfoliation syndrome, characterized by the deposition of microfibrillar material throughout the eye, is a significant risk factor for glaucoma, with over 50% of affected individuals developing IOP and optic nerve degeneration by 70 years of age (70). Exfoliation syndrome is inherited as a complex trait, and a genome-wide association study using cases and controls from Iceland initially identified lysyl oxidase-like 1 (LOXL1) as a major genetic risk factor for the condition (71), with a population-attributable risk of more than 99%. Subsequently, this association has been replicated in populations throughout the world (72–76). Importantly, although the risk allele (G153D) is present in the majority of cases, it is also highly prevalent in controls, indicating that LOXL1 is necessary but not sufficient for the disease and that other genetic and/or environmental factors are required for disease development (77). LOXL1 is a member of the lysyl oxidase family of proteins that catalyze the polymerization of tropoelastin to form the mature elastin polymer (78). Elastin fibers are a major component of many structures in the eye, such as the ECM of the trabecular meshwork and the lamina cribrosa of the optic nerve (79, 80). LOXL1 is also involved in elastin homeostasis and renewal and participates in spatially organizing elastogenesis at sites of elastin deposition (81). The role of the G153D risk allele in disease development is not yet clear, and recent studies suggest that the risk allele in the black South African population is reversed compared with other populations, arguing that neither the Glycine allele or the Aspartate allele is biologically causative (82). Interestingly, the LOXL1-null mouse has some features of the human disease, including lens and iris abnormalities, but does not exhibit increased IOP or optic nerve damage (unpublished observations).

**POAG.** Genome-wide association studies in Japanese populations (83) and Caribbean populations of African descent (84) have identified (SNPs) with possible POAG association, but these have not revealed specific gene associations. Future genome-wide association studies with sufficient power to detect genes of moderate effect will provide important information about the genes contributing to this complex condition (unpublished observations).

**Pathophysiology associated with current glaucoma genes**

Most of the current glaucoma genes cause early-onset forms of glaucoma characterized by severely elevated IOP. Most of these genes (CYP1B1, LTPB2, PITX2, FOXC1, PAX6, and LMX1B) modulate ocular developmental processes, and gene mutations lead to abnormal development of the anterior segment structures necessary for aqueous humor removal (20). The MYOC gene, coding for myocilin, is the only gene currently known to cause elevated IOP with normal development of the ocular anterior segment (40). It is

### Table 2

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Chromosome location</th>
<th>Condition</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADRB1</td>
<td>β1-adrenergic receptor</td>
<td>10q24-q26</td>
<td>NTG</td>
<td>131</td>
</tr>
<tr>
<td>ADRB2</td>
<td>β2-adrenergic receptor</td>
<td>5q32-q34</td>
<td>Adult-onset POAG</td>
<td>131</td>
</tr>
<tr>
<td>APOE</td>
<td>Apolipoprotein E</td>
<td>19q13.2</td>
<td>NTG</td>
<td>132</td>
</tr>
<tr>
<td>CYP46A1</td>
<td>Cytochrome P450, family 46, subfamily A, polypeptide 1</td>
<td>14q32.1</td>
<td>Adult-onset POAG</td>
<td>133</td>
</tr>
<tr>
<td>EDNRA</td>
<td>Endothelin receptor, type A</td>
<td>4q31.2</td>
<td>NTG</td>
<td>134A</td>
</tr>
<tr>
<td>HSPA1A</td>
<td>Heat-shock 70-kD protein 1A</td>
<td>6p21.3</td>
<td>Adult-onset POAG; NTG</td>
<td>135A</td>
</tr>
<tr>
<td>IGF2</td>
<td>Insulin-like growth factor II</td>
<td>11p15.5</td>
<td>Adult-onset POAG</td>
<td>136</td>
</tr>
<tr>
<td>MTHFR</td>
<td>5,10-methylenetetrahydrofolate reductase</td>
<td>1p36.3</td>
<td>Adult-onset POAG; NTG</td>
<td>137A</td>
</tr>
<tr>
<td>MFN1</td>
<td>Mitofusin 1</td>
<td>3q25-q26</td>
<td>NTG</td>
<td>138</td>
</tr>
<tr>
<td>MFN2</td>
<td>Mitofusin 2</td>
<td>1p36.2</td>
<td>NTG</td>
<td>138</td>
</tr>
<tr>
<td>NOS3</td>
<td>Nitric oxide synthase 3</td>
<td>7q36</td>
<td>Adult-onset POAG</td>
<td>69</td>
</tr>
<tr>
<td>OLFM2</td>
<td>Offactomedin 2</td>
<td>19p13.2</td>
<td>Adult-onset POAG</td>
<td>139</td>
</tr>
<tr>
<td>OPA1</td>
<td>Optic atrophy 1</td>
<td>3q28-q29</td>
<td>NTG</td>
<td>140A</td>
</tr>
<tr>
<td>PARL</td>
<td>Presenilin-associated, rhomboid-like protein</td>
<td>3q27</td>
<td>NTG</td>
<td>138</td>
</tr>
<tr>
<td>PON1</td>
<td>Paraoxonase 1</td>
<td>7q21.3</td>
<td>NTG</td>
<td>141</td>
</tr>
<tr>
<td>TAP1</td>
<td>Transporter, ATP-binding cassette, major histocompatibility complex, 1</td>
<td>6p21.3</td>
<td>Adult-onset POAG</td>
<td>142</td>
</tr>
<tr>
<td>TLR4</td>
<td>Toll-like receptor 4</td>
<td>9q32-q33</td>
<td>NTG</td>
<td>143</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
<td>6p21.3</td>
<td>Adult-onset POAG</td>
<td>144</td>
</tr>
<tr>
<td>TPS3</td>
<td>Tumor protein p53</td>
<td>17p13.1</td>
<td>Adult-onset POAG</td>
<td>144</td>
</tr>
</tbody>
</table>

*If more than one case-control association study for the selected gene has been published, the most recent report is cited.*
expected that certain glaucoma-predisposing genes will specifically influence ganglion cell death in the setting of elevated IOP or even normal IOP. Ganglion cell apoptosis is associated with a mutant form of optineurin (56, 57), and WDR36 variants may increase the risk factors for glaucoma, including central corneal thickness, IOP, and anatomic features of the optic nerve. The heritability estimate, which in most patients is related to the rate and extent of ganglion cell loss, is 0.35 for IOP, 0.55 for optic cup diameter, 0.57 for optic disc diameter, 0.58 for vertical cup-to-disc ratio, 0.39 for neuroretinal rim area, 0.48 for retinal nerve fiber layer thickness, and 0.68 for central corneal thickness (91–94).

Figure 2
Schematic overview of experimental therapeutic approaches to glaucoma, including intraocular delivery of neuroprotective molecules, viral-mediated gene transfer, and stem cell therapies.

A variety of studies have been performed to identify genetic determinants of ocular quantitative traits, including genome-wide linkage analyses for IOP, genome-wide association studies for optic nerve parameters, and gene-association studies for central corneal thickness. A number of genomic regions have been identified as IOP linkage regions (95), and several genes have been identified as possible candidates for influencing central corneal thickness (96), including common polymorphisms in the type I collagen genes, COL1A1 and COL1A2. Two of the IOP regions on chromosomes 2 and 19 overlap with regions identified as potential loci for blood pressure, suggesting factors that may participate in regulation of both IOP and blood pressure (95). Recently a genome-wide association study has identified a SNP located near the ATOH7 gene as a significant determinant of optic nerve size (97).

Biomarkers for glaucoma
Individuals predisposed to glaucoma should be identified at the earliest possible stages of the disease, so that treatment can be initiated before the optic nerve is irreversibly damaged. Although current therapy is not curative, for many patients lowering the IOP using currently available pharmaceutical and/or surgical approaches can slow the progression of the disease and limit the overall loss of vision. Thus, biomarkers might be invaluable tools to identify individuals at risk for disease and, depending on the approach, could serve to measure the outcomes of therapies. The development of clinically useful biomarkers is an area of active investigation and includes genetic screening tests, proteomic markers, and analyses of serum antibodies to retina and optic nerve proteins.

Genetic screening tests. Currently, genetic testing can identify individuals at risk for early-onset forms of glaucoma in approximately 30% of cases (98). Useful gene-based screening tests for adult-onset POAG are not yet available (99); however, ongoing studies using large case/control cohorts for genome-wide association, such as those discussed above, may reveal important genetic determinants that could lead to clinically relevant screening tests. Although a major gene (LOXL1) has been associated with adult-onset exfoliation glaucoma, use of the gene variants for genetic screening remains challenging. The high prevalence of the LOXL1 risk genotype in control populations confers an extremely low specificity, making it almost useless as a predictive screening test (77). The specificity of genetic testing is increased with a combination of the LOXL1 risk genotype and a variant in the 5′ promoter region; however, the positive predictive value remains low, as the specific 5′ variant is rare (unpublished observations).

Proteomic biomarkers. Proteomic approaches using serum, tears, and aqueous humor could identify useful glaucoma biomarkers (100). Analysis of serum antibodies to optic nerve or retinal proteins may detect glaucoma-specific autoantibodies that could be indicative of ganglion cell damage (101). However, the small amount of tissue affected by the disease is a limitation of using proteomics to identify a glaucoma biomarker with the specificity and sensitivity required for clinical use. Proteomic approaches may also be comprised by the confounding effects of concurrent medical and/or surgical treatments, as these therapies can also influence the protein composition of affected tissues (102).
and surgically, no treatment is currently available to prevent and restore retinal and optic nerve function. In addition to lowering IOP, neuroprotective strategies could effectively preserve vision in glaucoma. A variety of experimental approaches to promote retinal ganglion cell survival are underway, including intraocular delivery of neuroprotective molecules, viral-mediated gene transfer, and stem cell therapies (Figure 2).

**Intraocular delivery of neuroprotective molecules.** Neurotrophic agents are known to promote survival of retinal ganglion cells (103). In animal models, intravitreal injections of brain-derived neurotrophic factor can rescue retinal ganglion cells after optic nerve injury (104), although the long-term effects of those treatments and overall risks are not known (105). Recent experiments suggest that combinations of growth factors, such as the combination of brain-derived neurotrophic factor and LINGO-1 fusion protein, can provide more complete rescue of ganglion cells for longer periods of time (106). In addition, delivery of ciliary-derived neurotrophic factor, using viral transfer and injections of nerve growth factor in the episcleral veins, has been shown to be neuroprotective in a rat model of glaucoma (107, 108). Although current investigations are limited to animal models, these studies suggest that future clinical applications in human glaucoma patients could prevent ganglion cell damage and restore ganglion cell function.

**Gene replacement therapies.** Gene replacement therapies may specifically target the underlying molecular events responsible for the disease and, depending on the choice of viral vector, may have long-lasting local effects. The eye is easily accessible, making injectable viral-transfer methods an attractive therapeutic option. Indeed, the success of a viral-based gene delivery approach has been demonstrated in an ocular disease, Leber’s congenital amaurosis, caused by mutations in a retinal protein, RPE65 (109). As genetic studies continue to elucidate the underlying molecular events responsible for glaucoma, the use of gene-based therapies for pathology of the trabecular meshwork and of the retinal gangliaons cells are gaining support (110). Experimental gene-based therapies targeting the trabecular meshwork include the overexpression of recombinant matrix metalloproteinase I (MMP1) to counteract ECM deposition in patients affected by steroid-induced glaucoma (111). Lentiviral vectors have been used to deliver COX-2, a regulator of prostaglandin formation, to increase uveal scleral outflow of fluid (112). Self-complementary AAV has been shown to provide safe and long-term gene transfer to the trabecular meshwork in living rats and monkeys, making stable expression with minimal risks possible (113). Finally, intravitreal injection of viral constructs carrying neurotrophic factors have also successfully prevented ganglion cell loss in animal models of glaucoma (107), suggesting that viral gene-based therapy may be a viable approach to protect ganglion cells in glaucoma patients.

**Stem cell–based therapy.** Stem cells may be useful therapeutic agents for neurodegenerative diseases, because they congregate at the sites of injury and may provide chronic neuroprotection after a single treatment (114). Stem cell transplantation can supply neurotrophic factors and also modulate other components of the CNS environment to facilitate endogenous repair. Considerable progress in the understanding of the pathways involved in directed axon growth and the manipulation of stem and progenitor cells toward a RGC fate (115) suggest that stem cell therapies using mesenchymal stem cells and neural stem cells for glaucoma could be possible (116). Intravitreal injection of systemic bone marrow–derived mesenchymal stem cells in a rat glaucoma model resulted in an increase in overall RGC axon survival (117), and injection of neural stem cells (oligodendrocyte precursor cells) was also neuroprotective (118). In addition, at least one study suggests that stem cell transplantation may also improve fluid removal through the trabecular meshwork (119). Though many challenges remain, including identifying sources for suitable stem cells and determining the safety of therapeutic stem cell use, these and other recent studies suggest that stem cell transplantation could be a promising therapeutic approach for glaucoma.

**Future directions**

Novel cell-based and viral-gene-transfer therapies promise to bring new hope for visual preservation, but they may also bring significant risk. It will be important to carefully select patients who will benefit from these therapies. The ocular hypertensive treatment study, a clinical trial designed to evaluate the impact of topical IOP-lowering therapy on the onset of visual field loss and/or optic nerve damage in patients with elevated IOP, showed that only 10%–15% of patients with elevated IOP actually develop optic nerve disease (120, 121), and treatment should be targeted to those at increased risk for visual loss, which includes those individuals with older age, larger vertical or horizontal cup-disc ratio, higher IOP, greater visual field loss, and thinner central corneal measurement. Sufficiently sensitive and specific screening tools (genetic and/or proteomic biomarkers) will be needed to effectively identify individuals who will benefit from therapy. It is also important that treatment is initiated when it will have the most benefit. Technologies that will make it possible to monitor “sick” ganglion cells at stages when they can still be rescued need to be developed, and recent advances in retinal imaging, such as spectral domain optical coherence tomography, are promising (122). This technique creates a 3-dimensional image of the optic nerve, with sufficient resolution that structural changes in the optic nerve caused by glaucoma could be detected at early stages when therapeutic options could have maximal benefit. Real-time in vivo imaging of retinal cell apoptosis using intravitreal fluorescence-labeled annexin V, followed by microscopy, suggests that methods to identify ganglion cells entering apoptosis in glaucoma patients may be possible in the future (123). These technologies will also make it possible to determine the efficacy of therapy. In the future, we can expect that a patient’s risk for glaucoma will be established using genetic and other screening tests, an assessment of ganglion cell disease will be made by novel imaging technologies, and appropriate therapy will be initiated to restore ganglion cell health. Extension of the genetic studies summarized here will allow early disease detection and timely therapy targeted to molecular disease mechanisms, granting glaucoma patients the best chance to maintain useful sight.

**Acknowledgments**

This work was supported in part by NIH grants R01EY009847, R01EY015872, R21EY019161, and P30EY014104 and by Research to Prevent Blindness and the Massachusetts Eye Research Fund.

Address correspondence to: Janey L. Wiggs, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles St., Boston, Massachusetts, USA. Phone: 617.573.6440; Fax: 617.573.6439; E-mail: janey_wiggs@meei.harvard.edu.


47. Allingham RR, et al. Early-onset adult POAG review series


